Wells Fargo’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,459
| Closed | -$320 | – | 7794 |
|
|
2023
Q2 | $320 | Buy |
1,459
+105
| +8% | +$24 | ﹤0.01% | 6568 |
|
|
2023
Q1 | $426 | Sell |
1,354
-24
| -2% | -$17 | ﹤0.01% | 6596 |
|
|
2022
Q4 | $1.63K | Buy |
1,378
+47
| +4% | +$45 | ﹤0.01% | 6057 |
|
|
2022
Q3 | $1K | Buy |
1,331
+18
| +1% | +$28 | ﹤0.01% | 6539 |
|
|
2022
Q2 | $1K | Buy |
1,313
+30
| +2% | +$37 | ﹤0.01% | 6686 |
|
|
2022
Q1 | $3K | Sell |
1,283
-11
| -0.9% | -$21 | ﹤0.01% | 6624 |
|
|
2021
Q4 | $3K | Buy |
1,294
+23
| +2% | +$65 | ﹤0.01% | 6843 |
|
|
2021
Q3 | $4K | Hold |
1,271
| – | – | ﹤0.01% | 6465 |
|
|
2021
Q2 | $9K | Buy |
1,271
+5
| +0.4% | +$31 | ﹤0.01% | 6187 |
|
|
2021
Q1 | $7K | Buy |
1,266
+925
| +271% | +$6.25K | ﹤0.01% | 6432 |
|
|
2020
Q4 | $2K | Buy |
341
+9
| +3% | +$63 | ﹤0.01% | 6301 |
|
|
2020
Q3 | $2K | Sell |
332
-6
| -2% | -$42 | ﹤0.01% | 6160 |
|
|
2020
Q2 | $2K | Hold |
338
| – | – | ﹤0.01% | 6125 |
|
|
2020
Q1 | $2K | Buy |
338
+38
| +13% | +$242 | ﹤0.01% | 6027 |
|
|
2019
Q4 | $1K | Hold |
300
| – | – | ﹤0.01% | 6294 |
|
|
2019
Q3 | $2K | Hold |
300
| – | – | ﹤0.01% | 6223 |
|
|
2019
Q2 | $3K | Hold |
300
| – | – | ﹤0.01% | 6138 |
|
|
2019
Q1 | $3K | Hold |
300
| – | – | ﹤0.01% | 5832 |
|
|
2018
Q4 | $3K | Hold |
300
| – | – | ﹤0.01% | 6169 |
|
|
2018
Q3 | $4K | Buy |
+300
| New | +$3.88K | ﹤0.01% | 6157 |
|
Other funds holding ARDS
Wells Fargo's ARDS Position: Q3 2023 in Review
Wells Fargo sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q3 2023, closing a stake of 1,459 shares — an estimated $320 sold.
Wells Fargo first reported a position in ARDS in Q3 2018 and held it in 20 quarters. The position peaked at $9K in Q2 2021. 1 fund tracked by Wall St. Rank holds ARDS as of Q3 2023.
- Wells Fargo reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Wells Fargo sold 1,459 Aridis Pharmaceuticals Inc. Common Stock shares in Q3 2023, an estimated $320.
- Wells Fargo first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q3 2018 and held it in 20 quarters.
- Wells Fargo's Aridis Pharmaceuticals Inc. Common Stock position peaked at $9K in Q2 2021.
- 1 fund tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q3 2023.
Based on Wells Fargo's 13F filing for Q3 2023, filed 13 Nov 2023.